Its use is intended to lower cholesterol levels and prevent cardiovascular disease CVD such as heart attacks and strokes. Coronary heart disease alone accounts for one in every five deaths among adults 45 to 64 years old and a quarter of deaths among Americans 65 years and older. Crestor is part of a class of drugs called statins. These drugs are intended to eliminate the buildup of cholesterol in the arteries which obstructs blood flow through the body.
Crestor is part of a class of drugs called statins Crestor has been shown to reduce the risk of heart attack over 1. But there have been no long-term studies examining the effects of taking Crestor or other statins for as long as 20 to 30 years — the length of time many people prescribed a statin will have to take the medicine. There is debate among health care professionals over whether statins are prescribed too often or not enough.
Side effects have included muscle pain and damage, cataracts, kidney and liver damage and a possible increased risk for developing diabetes. Cholesterol is a white, waxy insoluble fat that moves through the bloodstream.
If these drugs are administered concurrently, monitor patients for signs of rosuvastatin toxicity, such as muscle aches, muscle pain or tenderness, general weakness or fatigue, side or back pain, or decreased urination.
Moderate Monitor for an increase in rosuvastatin-related adverse reactions, including rhabdomyolysis and myopathy, if coadministration with osimertinib is necessary. Moderate Raltegravir use has been associated with elevated creatinine kinase concentrations; myopathy and rhabdomyolysis have been reported.
Use raltegravir cautiously with drugs that increase the risk of myopathy or rhabdomyolysis such as HMG-CoA reductase inhibitors Statins. The administration of more than one HMG-CoA reductase inhibitor at one time would be duplicative therapy and perhaps increase the risk of drug-related toxicity including myopathy and rhabdomyolysis.
Moderate Use caution if coadministration of regorafenib with rosuvastatin is necessary, and monitor for an increase in rosuvastatin-related adverse reactions. Administration of regorafenib for 14 days prior to a single dose of rosuvastatin increased the mean AUC and Cmax of rosuvastatin by 3.
Moderate Avoid the concurrent use of rosuvastatin and rolapitant if possible; if coadministration is necessary, use the lowest effective dose of rosuvastatin and monitor for rosuvastatin-related adverse effects. Moderate Safinamide at the mg dose and its major metabolite may inhibit intestinal breast cancer resistance protein BCRP , which could increase plasma concentrations of BCRP substrates such as rosuvastatin.
Monitor patients for increased pharmacologic or adverse effects of BCRP substrates during concurrent use of safinamide, particularly the mg dose. Major The concurrent use of saquinavir boosted with ritonavir and rosuvastatin should be avoided if possible due to the potential for myopathies, including rhabdomyolysis. Coadministration of saquinavir boosted with ritonavir and rosuvastatin results in an increased plasma concentration of rosuvastatin.
If coadministered, use the lowest possible dose of rosuvastatin with careful clinical monitoring, Simeprevir: Moderate Coadministration of rosuvastatin with simeprevir, an inhibitor of the breast cancer resistance protein BCRP and OATP1B1 transporters, results in increased rosuvastatin plasma concentrations.
If these drugs are given together, initiate rosuvastatin therapy at 5 mg once daily; do not exceed 10 mg once daily. Closely monitor for statin-associated adverse reactions, such as myopathy and rhabdomyolysis.
Major Do not exceed a rosuvastatin dose of 10 mg daily with coadministration of velpatasvir as this may significantly increase the serum concentrations of rosuvastatin, which may increase the risk of myopathy and rhabdomyolysis. Major Avoid concurrent administration of voxilaprevir with rosuvastatin. Taking these drugs may significantly increase systemic exposure to rosuvastatin, which may increase the risk of myopathy and rhabdomyolysis.
Moderate The risk of developing myopathy during therapy with HMG-CoA reductase inhibitors may be increased when used with tacrolimus. Moderate If possible, stop use of rosuvastatin temporarily during treatment with oral tedizolid. If coadministration cannot be avoided, closely monitor for rosuvastatin-associated adverse events.
Moderate Close clinical monitoring is advised when administering rosuvastatin with telaprevir due to the potential for rosuvastatin-related adverse events. When used in combination, the plasma concentrations of rosuvastatin may be elevated. Monitor patients for any signs or symptoms of unexplained muscle pain, tenderness, or weakness, particularly during periods of upward dosage titration.
Coadministration of rosuvastatin with inhibitors of OATP, such as telithromycin may theoretically result in increased concentrations of rosuvastatin. Moderate Concurrent use of teriflunomide, an inhibitor of the hepatic uptake organic anion transporting polypeptide OATP1B1, with some HMG-CoA reductase inhibitors Statins , including atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin may increase the AUC of the statin.
Additive hepatotoxicity may occur. Caution should also be exercised when using combination dosage forms, such as amlodipine; atorvastatin, ezetimibe; simvastatin, lovastatin; niacin, niacin; simvastatin, and simvastatin; sitagliptin.
Monitor patients for signs of myopathy or hepatotoxicity. Major The risk of myopathy, including rhabdomyolysis, may be increased when tipranavir is given in combination with most HMG-CoA reductase inhibitors. If rosuvastatin is to be used concomitantly with tipranavir in the FDA approved dosage regimen , use the lowest possible dose with careful monitoring, or consider an alternative HMG-CoA reductase inhibitor that is less significantly metabolized by CYP3A4 i.
INR should be monitored at baseline prior to rosuvastatin initiation, and frequently following initiation of rosuvastatin therapy and subsequent dosage changes. Adjust warfarin dosage based on INR and clinical response. Once a stable INR is documented, INR can be monitored at the intervals otherwise recommended based on the indication for anticoagulation and co-existing conditions.
How to use Crestor Read the Patient Information Leaflet if available from your pharmacist before you start taking rosuvastatin and each time you get a refill. If you have any questions, ask your doctor or pharmacist. Take this medication by mouth with or without food as directed by your doctor, usually once daily. The dosage is based on your medical condition, response to treatment, age, race, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use including prescription drugs , nonprescription drugs, and herbal products.
If you are of Asian descent, your doctor may direct you to start with a lower dose because you may be more sensitive to its effects. Antacids containing aluminum or magnesium can reduce the absorption of this drug. Therefore, if taking this type of antacid, take it at least 2 hours after this medication. Take this medication regularly in order to get the most benefit from it. Remember to take it at the same time each day. It is important to continue taking this medication even if you feel well.
Most people with high cholesterol or triglycerides do not feel sick. It is very important to continue to follow your doctor's advice about diet and exercise. It may take up to 4 weeks before you get the full benefit of this drug. What conditions does Crestor treat? Round, pink coloured tablets, intagliated with 'ZD' and '20' on one side and plain on the reverse. Oval, pink coloured tablets, intagliated with 'ZD' on one side and '40' on the reverse.
Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments e. LDL apheresis or if such treatments are not appropriate. Prevention of Cardiovascular Events Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event see section 5. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.
Crestor may be given at any time of day, with or without food. The choice of start dose should take into account the individual patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions see below. A dose adjustment to the next dose level can be made after 4 weeks, if necessary see section 5. In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses see section 4. Specialist supervision is recommended when the 40 mg dose is initiated.
Prevention of cardiovascular events In the cardiovascular events risk reduction study, the dose used was 20 mg daily see section 5. Paediatric population Paediatric use should only be carried out by specialists. Safety and efficacy of doses greater than 10 mg have not been studied in this population. Safety and efficacy of doses greater than 20 mg have not been studied in this population. Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations see section 4.
Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment. Homozygous familial hypercholesterolaemia In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.
A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations see section 4.
There is limited experience with doses other than 20 mg in this population. The 40 mg tablet is not suitable for use in paediatric patients. Children younger than 6 years The safety and efficacy of use in children younger than 6 years has not been studied.
Therefore, Crestor is not recommended for use in children younger than 6 years. No other dose adjustment is necessary in relation to age. Side effects that you should report to your doctor or health care professional as soon as possible: Call your doctor for medical advice about side effects. Where should I keep my medicine? Keep out of the reach of children. Store at room temperature between 20 and 25 degrees C 68 and 77 degrees F.
Keep container tightly closed protect from moisture. Throw away any unused medicine after the expiration date. This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider. I have saved a lot of money using Planet Drugs Direct, and I am going to keep on using them.
In Canada - Call your doctor for calcium advice about side effects. This document does not contain all possible drug interactions. If you are of Asian descent, your doctor may direct you to start with a lower dose because you may be more sensitive 20mg its effects. Because of the possible risk to the infantbreast -feeding while using this drug is not recommended. Crestor 5mg was created to accommodate the allowed intake of statins in Asian patients Studies have found heightened responses to therapeutic drugs among Asian patients. The task force based its recommendations on age and CVD rosuvastatin factors. If you miss a dose of this medicine, take it rosuvastatin soon as you remember. However, get calcium help right away if you notice any symptoms of a crestor allergic reactioncrestor rosuvastatin calcium 20mg, including: The effects of aprepitant on tolbutamide were not considered significant. Major The lowest dose of rosuvastatin should be considered if coadministered with clarithromycin. HMG-CoA reductase inhibitors decrease the 20mg of cholesterol and possibly crestor products of the cholesterol biosynthesis pathway; other adverse effects to a nursing infant are possible. Copyright c First Databank, Inc, crestor rosuvastatin calcium 20mg. Storage Store at room temperature away from light and moisture. Major Do not exceed a maximum rosuvastatin dose of 10 mg when coadministered with pibrentasvir due to an increased risk of myopathy, including rhabdomyolysis. Stay on this diet when you viagra cialis 40mg this medicine. Major Avoid concurrent administration of voxilaprevir with rosuvastatin.
© Copyright 2017 Crestor rosuvastatin calcium 20mg *** Generic Equivalent To Crestor 20mg.